Investing in biotech stocks can be risky due to the high stakes involved. Opus Genetics, a clinical-stage biopharmaceutical company, is valued at $1.4 billion and focuses on gene therapies to prevent blindness. The stock has surged 60.3% this year, with a potential 285% increase according to analysts. EyePoint Pharmaceuticals, also valued at $1.4 billion, is developing treatments for retinal diseases, with a 107.5% year-to-date gain. Their lead program, DURAVYU, is in Phase 3 trials, and analysts predict a potential 105.1% increase in stock value. Both companies present high-risk, high-reward opportunities in the biotech sector.

Read more at Barchart: The 2 Riskiest Stocks Investors Are Betting On With Over 300% Upside